<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148575">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166191</url>
  </required_header>
  <id_info>
    <org_study_id>BRONC 45.1,5</org_study_id>
    <nct_id>NCT01166191</nct_id>
  </id_info>
  <brief_title>Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)</brief_title>
  <official_title>Concurrent Chemo-radiotherapy With IMRT for Stage I-III Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' group was the first to perform a phase II trial in patients with limited
      disease (stage I-III) small-cell lung carcinoma (SCLC) in which only the
      fluorodeoxyglucose-positron emission tomography (FDG-PET) positive lymph nodes were
      irradiated. In this trial, only 3% of isolated nodal failures were observed. However, all
      patients in that study were treated with 3D conformal radiotherapy (3DCRT). At present, IMRT
      techniques have become more standard in lung cancer. Because of the lower radiation dose to
      the lymph nodes outside of the planning target volume (PTV) with IMRT, higher incidences of
      isolated nodal failures may occur. In this trial, the investigators will investigate the
      patterns of local relapse after IMRT with concurrent chemotherapy in patients with stage
      I-III SCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients (see below) will receive radiotherapy to the primary tumor and the
      initially involved mediastinal lymph nodes on FDG-PET scan to a dose of 45Gy in 30 fractions
      in 3 weeks (1.5Gy BID). Radiotherapy will be delivered concurrently with cisplatin (or in
      case of a creatinin clearance of &lt;60ml/min, carboplatin) and etoposide chemotherapy. When
      after 4 cycles of chemotherapy and concurrent chest radiotherapy, no disease progression is
      observed and the WHO performance status is 0-2, PCI (prophylactic cranial irradiation) will
      bee offered to a dose of 25 Gy in 10 daily fractions.

      The radiation doses will be specified according to ICRU 50. Lung density corrections will be
      applied, as well as all standard QA procedures. Technical requirements are the same as in
      standard practice at MAASTRO clinic.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Isolated nodal failures</measure>
    <time_frame>18 months</time_frame>
    <description>Proportion of isolated nodal failures 18 months post-radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea (CTCAE 4.0)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysphagia (CTCAE 4.0)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stage I-III Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy</description>
    <arm_group_label>SCLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological of cytological proven SCLC

          -  UICC stage I-III, which are amendable for radical local treatment

          -  Performance status 0-2

          -  IMRT technique

        Exclusion Criteria:

          -  Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma)

          -  Stage IV

          -  Performance status 3 or more

          -  No IMRT technique
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk De Ruysscher, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dirk De Ruysscher, MD, PhD</last_name>
    <phone>+31 88 44 55 700</phone>
    <email>dirk.deruysscher@maastro.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chantal Overhof</last_name>
    <phone>+31 88 44 55 686</phone>
    <email>chantal.overhof@maastro.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MAASTRO clinic</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk De Ruysscher, MD, PhD</last_name>
      <phone>+31 88 4455700</phone>
      <email>dirk.deruysscher@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Chantal Overhof</last_name>
      <phone>+31 88 44 55 686</phone>
      <email>chantal.overhof@maastro.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Dirk De Ruysscher, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 27, 2016</lastchanged_date>
  <firstreceived_date>July 19, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>SCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
